Nazarenko Alina S, Biryukova Yulia K, Trachuk Kirill N, Orlova Ekaterina A, Vorovitch Mikhail F, Pestov Nikolay B, Barlev Nick A, Levaniuk Anna I, Gordeychuk Ilya V, Lunin Alexander S, Demyashkin Grigory A, Shegai Petr V, Kaprin Andrei D, Ishmukhametov Aydar A, Kolyasnikova Nadezhda M
Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of RAS (Institute of Poliomyelitis), Moscow 108819, Russia.
Department of Organization and Technology of Production of Immunobiological Preparations, Institute for Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 117418, Russia.
Vaccines (Basel). 2025 Jan 6;13(1):40. doi: 10.3390/vaccines13010040.
: We evaluate the immunotherapeutic potential of the yellow fever virus vaccine strain 17D (YFV 17D) for intratumoral therapy of pancreatic cancer in mice. : The cytopathic effect of YFV 17D on mouse syngeneic pancreatic cancers cells were studied both in vitro and in vivo and on human pancreatic cancers cells in vitro. : YFV 17D demonstrated a strong cytopathic effect against human cancer cells in vitro. Although YFV 17D did not exhibit a lytic effect against Pan02 mouse cells in vitro, a single intratumoral administration of 17D caused a delay in tumor growth and an increase in median survival by 30%. Multiple injections of 17D did not further improve the effect on tumor growth; however, it notably extended the median survival. Furthermore, preliminary immunization with 17D enhanced its oncotherapeutic effect. : Intratumoral administration of yellow fever virus vaccine strain 17D delayed tumor in a murine model of pancreatic cancer. The fact that YFV 17D in vitro affected human cancer cells much more strongly than mouse cancer cells appears promising. Hence, we anticipate that the in vivo efficacy of YFV-17D-based oncolytic therapy will also be higher against human pancreatic carcinomas compared to its effect on the mouse pancreatic tumor.
我们评估了黄热病病毒疫苗株17D（YFV 17D）对小鼠胰腺癌进行瘤内治疗的免疫治疗潜力。研究了YFV 17D对小鼠同基因胰腺癌细胞的细胞病变效应，包括体外和体内实验，以及对人胰腺癌细胞的体外实验。YFV 17D在体外对人癌细胞表现出强烈的细胞病变效应。虽然YFV 17D在体外对Pan02小鼠细胞未表现出裂解作用，但瘤内单次注射17D可导致肿瘤生长延迟，中位生存期延长30%。多次注射17D并未进一步改善对肿瘤生长的影响；然而，它显著延长了中位生存期。此外，用17D进行初步免疫可增强其肿瘤治疗效果。在胰腺癌小鼠模型中，瘤内注射黄热病病毒疫苗株17D可延缓肿瘤生长。YFV 17D在体外对人癌细胞的影响比小鼠癌细胞强烈得多，这一事实似乎很有前景。因此，我们预计基于YFV-17D的溶瘤治疗对人胰腺癌的体内疗效也将高于其对小鼠胰腺肿瘤的疗效。
